Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial

Alexander Waits 1,2,*, Jau-Yuan Chen 3,4,*, Wei-Hong Cheng 5, Jih-I Yeh 6, Szu-Min Hsieh 7, Charles Chen 1, Robert Janssen 8, Chia En Lien 1,2,*, Tzou-Yien Lin 9,*,

1 Medigen Vaccine Biologics Corporation, Taipei, Taiwan
2 Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan
3 College of Medicine, Chang Gung University, Taoyuan, Taiwan
4 Department of Family Medicine, Chang Gung Memorial Hospital Linkou Branch, Taoyuan City, Taiwan
5 Department of Hematology and Oncology, Cancer Center, Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan
6 Department of Family Medicine, Hualien Tzu Chi Hospital, Hualien County, Taiwan
7 Department of Internal Medicine, Division of Infectious Diseases, National Taiwan University Hospital, Taipei City, Taiwan
8 Dynavax Technologies Corporation, Emeryville, CA 94608, U.S.A.
9 Department of Pediatrics, Chang Gung Memorial Hospital Taoyuan Branch, Taoyuan City, Taiwan

ARTICLE INFO

Article history:
Received 5 August 2022
Revised 22 August 2022
Accepted 23 August 2022

Keywords:
MVC-COV1901 vaccine
Older adults
Immunogenicity
SARS-Cov-2
Immunosenescence

ABSTRACT

Introduction: Older adults are subject to higher COVID-19 infection and mortality rates. Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated in phase 2 clinical trial for the general population, and negative correlations have been observed between immune responses and age, however, older adults were under-represented.

Methods: A double-blind, randomized, multi-center study compared safety and immunogenicity of high-dose (25 mcg) to mid-dose (15 mcg) of MVC-COV1901 administered 2 times 28 days apart in 420 participants of 65 years and older. The results have been stratified by the comorbidity status.

Results: Both high and mid-dose regimens elicited mostly mild adverse events and robust immune responses when measured as neutralizing and binding antibodies titers. High doses elicited better immune responses in the group without comorbidities.

Conclusion: Given the general population-associated safety and immunogenicity of MVC-COV1901, we recommend high dose for immunization of older adults with MVC-COV1901. The clinical trial was registered at https://clinicaltrials.gov/ (NCT04822025).

© 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Since the outbreak of the COVID-19 pandemic, the highest death rates have been consistently recorded among people older than 65 years old (World Health Organization, 2022). Although multiple countries prioritized older adults in the national vaccination strategies against SARS-CoV-2 (Our World in Data, 2022), an increase in breakthrough COVID-19 infections was found among older adults (Haas et al., 2021). Moreover, several studies identified older age as a substantial barrier for vaccine uptake due to lack of trust, which could constrain vaccination coverage of this vulnerable population (Jantzen et al., 2022; Siu et al., 2022; Tan et al., 2022).

Whereas older population generally shows weaker immune response to vaccines due to immunosenescence (McElhaney et al., 2020; Schenkelberg, 2021; Soiza et al., 2021), the effect of age on COVID-19 vaccines immunogenicity has not been studied extensively. Pfizer BioNTech BNT162b2 clinical trials reported robust negative correlations between post-vaccination antibody responses and age (Li et al., 2021; Naaber et al., 2021). Neutralizing antibodies titers declined faster in older adults after two doses of AstraZeneca ChAdOx1 (Anderson et al., 2020). However, the results of AstraZeneca ChAdOx1 and Moderna mRNA-1273 trials were in-

* Corresponding author: Chia-En Lien, Medigen Vaccine Biologics, Taipei 114, Taiwan.
* Co-corresponding author: Tzou-Yien Lin, Department of Paediatrics, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
E-mail addresses: Allenlien@medigenvac.com (C.E. Lien), Alinpid@gmail.com (T.-Y. Lin).
Both authors contributed equally to the first authorship.
conclusive about the effect of age on SARS-CoV-2 neutralizing and binding antibodies titers (Anderson et al., 2020; RamaSamy et al., 2020). Even less is known about the effect of age on efficacy of other COVID-19 vaccines.

MVC-COV1901 is a protein subunit vaccine using the prefusion stabilized spike protein S-2P adjuvanted with CPG 1018 and aluminum hydroxide (Hsieh et al., 2021). An MVC-COV1901 dose of 15 mcg S-2P has shown favorable safety profile and robust immunogenicity in a phase 2 clinical trial and has been approved for use in Taiwan since August 2021 (Hsieh et al., 2021). The post-hoc analysis of this trial data revealed negative correlations between age and the antibody titers in 903 healthy adults from 20 to 87 years of age (Lien et al., 2021). The live-virus neutralization assay 28 days after the second dose showed a trend of decreasing immune responses to the vaccine as age increases. Older age groups also demonstrated a slower increase in binding antibodies titers from the first dose administration to 28 days after the second dose (Lien et al., 2021).

Older populations are often under-represented in most vaccine studies which generally exclude or only include a smaller proportion of older adults among the wider target population (Veronese et al., 2021). To more rigorously assess safety and immunogenicity of MVC-COV1901 vaccine in participants of 65 years and older, a double-blind, randomized study compared high-dose (25 mcg S-2P) to mid-dose (15 mcg S-2P) of MVC-COV1901. Stratification by comorbidities, such as cancer, chronic kidney disease, heart conditions, etc., was performed to better understand response to the vaccination in the more fragile subpopulations of this study.

**Methods**

A prospective, randomized, dose-comparison, multi-center, double-blinded phase 2 trial was conducted at four hospitals in Taiwan. Participants were male or female of ≥ 65 years of age at randomization, healthy or with pre-existing medical conditions in stable condition; had not travelled oversea within 14 days prior to screening and consented to not travel oversea throughout the study period; provided written informed consent to participate in the study. Prior to the first dose of study intervention, participants must not have received any investigational intervention, licensed live-attenuated vaccines, licensed non-live-attenuated vaccines, blood product or intravenous immunoglobulin, coronavirus vaccine, immunosuppressive or immune-modifying therapy, treatment with tumor necrosis factor (TNF)-α, major surgery or any radiation therapy within the pre-specified time frame. Participants must not have the pre-specified medical conditions including immunosuppressive illness, history of malignancy, bleeding disorder, uncontrolled human immunodeficiency virus (HIV) infection, SARS-CoV-1 or -2 virus infections, allergy to any vaccine, fever, and any other acute or serious medical conditions which would interfere with adherence to study requirements.

The participants were randomized to receive either mid-dose (15 mcg) or high-dose (25 mcg) MVC-COV1901 in a 3:1 ratio. Randomization of participants was stratified by the presence or absence of comorbidity (comorbidity status: yes or no). Participants who had comorbidities that increased the risk of severe COVID-19 disease were defined as those who were diagnosed with at least one of the following before randomization – cancer, chronic kidney disease, chronic obstruction pulmonary disease, heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies, obesity (body mass index ≥ 30 kg/m²), sickle cell disease, type 2 diabetes mellitus with hemoglobin A1c (HbA1C) > 8% at screening visit (Centers for Disease Control and Prevention, 2022). All participants were centrally assigned to randomized study intervention using an interactive web response system with login passwords to ensure blinding for participants and investigators.

**Intervention and outcomes of interest**

Each participant received two doses of mid-dose or high-dose MVC-COV1901, administered 28 days apart via intramuscular injection in the deltoid region at Day 1 and Day 29. Participants were given a diary card and instructed to record any solicited (local, systemic) and unsolicited adverse events. The severity of AEs was assessed based on the extent to which it affected participant’s daily activities, as defined in the modified guidance from the US FDA (US Food and Drug Administration 2022).

The blood samples of randomized participants collected at Days 1 and 57 were measured for anti-SARS-CoV-2 neutralizing antibody titers against pseudovirus and/or live virus. The detection and characterization of neutralizing antibodies were performed by central laboratories using validated pseudovirus and/or live virus neutralization assays. The serum samples of randomized participants collected at Days 1, 29, and 57 were measured for antigen-specific immunoglobulin titers to S-2P protein. The detection and characterization of antigen-specific immunoglobulin were performed by a central laboratory using a validated enzyme-linked immunosorbent assay (ELISA) method.

**Statistical methods**

Safety set included all the participants who received at least one intervention and was used in the analysis of adverse events. Sample size for this study was not based on the formal assumptions in the absence of the relevant research. Power analysis with 300 participants showed a 95% probability to observe at least one participant with an AE if the true incidence of the AE was 1% and a 78% probability if the true incidence of the AE was 0.5%. Immunogenicity was assessed for per-protocol set, which included all the participants who received two doses of intervention and had valid antibody tests. Demographic characteristics, health status, and adverse events in the mid- and high-dose groups have been summarized as means/standard deviations for continuous and frequency/percentage for categorical values. Antibodies titers were expressed as geometrical means (GMT). The comparisons between antibodies titers were based on GMT ratios. The GMT ratios with two-sided 95% confidence intervals were calculated by exponentiating the mean difference of the natural log-transformed titers (follow-up visit minus the baseline, the high-dose group minus the mid-dose group group) and the corresponding confidence intervals, derived from two-samples t-test. P-values < 0.05 indicated statistical significance, and p-values<0.10 indicated marginal statistical significance. The data were analyzed using SAS version 9.4 or later.

**Results**

**Study design and participants**

During May 20–June 24 of 2021, 444 participants of age≥65 were screened and 420 were randomly assigned to receive a high-dose (25 mcg S-2P) (n=315) or mid-dose (15 mcg S-2P) (n=105) of MVC-COV1901 vaccine. One participant was randomized to the high-dose MVC-COV1901 group, but received the mid-dose MVC-COV1901, thus the safety set comprised 314 (99.7%) participants and 106 (101.0%) participants, who received high-dose and mid-dose MVC-COV1901, respectively. Up to the data cutoff date (October 21, 2021), a total of 405 participants (305 in the high-dose group and 100 in the mid-dose group) fulfilled the criteria for inclusion in the per-protocol immunogenicity subset (Fig. 1). The
mean age of participants in the safety set was 70.6 years (standard deviation (SD) 4.5; range 65–88 years), with 209 men (49.8%) and 211 women (50.2%). All the participants were Asians. Most participants had negative serology tests for HBsAg and hepatitis C virus. A total of 149 (35.5%) participants had comorbidities, the most common of which were chronic kidney disease (43 [10.2%]), cardiovascular disease [38 [9.0%]], obesity [38 [9.0%]], followed by cancer [26 [6.2%]), type 2 diabetes [19 [4.5%]), and chronic obstruction pulmonary disease [17 [4.0%]) (Table 1).

Occurrence of mostly mild adverse events implies MVC-COV1901 safety for older adults

The occurrence of solicited adverse events is summarized in Fig. 2a and in supplementary Tables S1 and S2. Overall, 216 (51.4%) of 420 participants reported solicited local adverse events after receiving any dose of the study intervention. The high-dose group (168 [53.5%] of 314) outnumbered the mid-dose group (48 [45.3%] of 106) in the number of solicited local adverse events, which were mostly mild (grade 1) in severity. After any dose of MVC-COV1901, the most common solicited local adverse event was pain/tenderness at the injection site (162 [51.6%] in the high-dose group compared with 47 [44.3%] in the mid-dose group). Solicited systemic adverse events were reported in 163 (38.8%) of 420 participants. The most common solicited systemic adverse events were myalgia [66 [21.0%] in the high-dose group compared with 27 [25.5%] in the mid-dose group] and malaise/fatigue [66 [21.0%] in the high-dose group compared with 21 [19.8%] in the mid-dose group]. Fever was reported in only one participant (0.2%). The mean onset day of solicited adverse events was ≤ 3 days after the first and second dose of study intervention, with a mean duration of ≤ 3 days. A total of 121 (28.8%) of 420 participants reported 195 unsolicited adverse events (supplementary Table S3). Four (1.3%) participants in the high-dose group reported 6 unsolicited adverse events of ≥ Grade 3. No unsolicited adverse event of severity ≥ Grade 3 was related to the study intervention. No deaths or vaccine-associated enhanced disease were reported.

The proportions of solicited (supplementary Tables S4 and S5) and unsolicited (supplementary Table S6) AEs in participants with (Fig. 2b) and without (Fig. 2c) comorbidities did not differ no-

---

**Table 1**

Demographics and baseline characteristics of the participants in the safety set (N=420).

|                      | MVC-COV1901 high-dose (25 mcg S-2P), n=314 | MVC-COV1901 mid-dose (15 mcg S-2P), n=106 |
|----------------------|-------------------------------------------|------------------------------------------|
| Mean age, years      | 70.5 (4.6)                                | 70.7 (4.3)                               |
| Sex                  |                                            |                                          |
| Females              | 162 (51.6)                                | 49 (46.2)                                |
| Males                | 152 (48.4)                                | 57 (53.8)                                |
| Mean body-mass index, kg/m² | 25.1 (3.8)                        | 25.0 (3.4)                               |
| HBsAg                | 29 (9.2)                                  | 6 (5.7)                                  |
| Hepatitis C antibodies | 7 (2.2)                              | 4 (3.8)                                  |
| Comorbidities        |                                            |                                          |
| Any                  | 112 (35.7)                                | 37 (34.9)                                |
| Cancer               | 19 (6.1)                                  | 7 (6.6)                                  |
| Chronic kidney disease | 36 (11.5)                          | 7 (6.6)                                  |
| Chronic obstruction pulmonary disease | 11 (3.5)                           | 6 (5.7)                                  |
| Cardiovascular disease | 24 (7.6)                             | 14 (13.2)                                |
| Obesity              | 30 (9.6)                                  | 8 (7.5)                                  |
| Type 2 diabetes mellitus with HbA1C > 8% at screening visit | 17 (5.4) | 2 (1.9) |

Data are presented as mean (standard deviation) for continuous variables (age, body-mass index), or n (%) for categorical variables. The safety set included all participants who had received at least one dose of MVC-COV1901 vaccine.

---

**Fig. 1.** Study design.
Comorbidities set. Include MD (95% GMT CI 82.7–116.5) and MD (95% GMT CI 113.2–136.0), Per-protocol analysis showed the respective GMT of 56041 (95% CI 45871–6846.7) and the GMT ratio of 111.08 (95% CI 90.98–135.62) (Fig. 3b). Both groups with and without comorbidities showed comparable GMT and GMT ratios to the baseline on day 29 and day 57 (Fig. 3).

Table 2 summarizes GMT ratios of high- to mid- dose 28 days after the second dose. Neutralizing antibodies GMT ratio was significantly (p-value < 0.05) above one (GMT ratio = 1.26, 95% CI 1.05–1.52). Stratification showed higher and significant GMT ratio for the group without comorbidities (GMT ratio = 1.30, 95% CI 1.03–1.65) versus the group with comorbidities (GMT ratio = 1.20, 95% CI 0.88–1.64). Binding antibody GMT ratio showed marginally (p-value < 0.10) significant increase in high-dose versus mid-dose with GMT ratio = 1.24 (95% CI 0.99–1.56). The group without comorbidities showed higher GMT ratio of 1.33 (95% CI 0.99–1.77) versus the group with comorbidities (GMT ratio = 1.09, 95% CI 0.77–1.56).

Fig. 2. Solicited local and systemic adverse events occurring within 7 days after first and second dose of MVC-COV1901 vaccine in mid- and high-dose groups in the safety set. (a) Safety set with all the participants (N=420); (b) Safety set with any comorbidities (n=149); (c) Safety set without any comorbidities (n=271). The comorbidities include cancer, chronic kidney disease, chronic obstruction pulmonary disease, heart conditions, obesity. Adverse events were graded as mild (grade 1), moderate (grade 2), or severe (grade 3).

Fig. 3. Immunogenicity of high and mid dose MVC-COV1901 vaccine in 65-88 years old. (a) Neutralizing antibody titers (NT50) against SARS-CoV-2. (b) Binding antibody titers (lgg) against SARS-CoV-2. Error bars represent 95% confidence intervals of the geometric mean titers. Black dotted lines represent lower and upper limits of detection. Comorbidities include cancer, chronic kidney disease, chronic obstruction pulmonary disease, heart conditions, obesity. HD – high dose, 25mcg 5-2P of MVC-COV1901 vaccine; MD – mid-dose, 15 mcg 5-2P of MVC-COV1901 vaccine.

Table 2 summarizes GMT ratios of high- to mid- dose 28 days after the second dose. Neutralizing antibodies GMT ratio was significantly (p-value < 0.05) above one (GMT ratio = 1.26, 95% CI 1.05–1.52). Stratification showed higher and significant GMT ratio for the group without comorbidities (GMT ratio = 1.30, 95% CI 1.03–1.65) versus the group with comorbidities (GMT ratio = 1.20, 95% CI 0.88–1.64). Binding antibody GMT ratio showed marginally (p-value < 0.10) significant increase in high-dose versus mid-dose with GMT ratio = 1.24 (95% CI 0.99–1.56). The group without comorbidities showed higher GMT ratio of 1.33 (95% CI 0.99–1.77) versus the group with comorbidities (GMT ratio = 1.09, 95% CI 0.77–1.56).
**Discussion**

This phase 2, randomized, double-blind, dose-comparison, multi-center clinical trial demonstrated safety and immunogenicity of MVC-COV1901 vaccine in older adults with and without comorbidities. A two-dose regimen of the high or mid-dose vaccine administered 28 days apart was found to be generally safe. Reactogenicity was mostly mild, and only a few cases in the high-dose group reported severe AEs such as myalgia, headache or nausea. Solicited local AEs were slightly more prevalent in the high-dose group, and systemic AEs were slightly more prevalent in the mid-dose group after the second dose. No substantial differences were observed in solicited and unsolicited AEs between those with and without comorbidities. MVC-COV1901 reactogenicity was slightly milder than in participants older than 65 who received two doses of NVX-CoV2373 subunit vaccine (Formica et al., 2021; Masuda et al., 2022). Notably, reactogenicity observed in our study was comparable with the NVX-CoV2373 clinical trial conducted, like our study, entirely with Asian older adults in Japan, even though the Japanese trial had a smaller sample size (Masuda et al., 2022).

Favorable immune responses were observed in both high and mid-dose groups, especially after the second dose, as indicated by the increase in neutralizing and binding antibody titers which suggests high vaccine efficacy (Khoury et al., 2021). High-dose elicited slightly higher immune responses relative to baseline than in the mid-dose group. Lack of the statistical significance between the dosages in our study may be attributed to highly heterogenous immune response in older adults, as was demonstrated in another subunit vaccine trial (Heath et al., 2021). However, GMT ratio of high to mid-dose groups 28 days after the second dose of MVC-COV1901 vaccine was significantly higher than one and favored the high-dose regimen. Previously, a phase 2 study reported that 2 different doses of NVX-CoV2373 (5-µg or 25-µg) delivered 21 days apart both elicited robust immune response in older adults, however, no formal statistic test have been performed to compare the regimens (Formica et al., 2021). Future trials may need to increase sample size to capture the dose-response relationships.

Further stratification of our analysis by presence of comorbidities revealed that high dose elicited slightly better immune responses in the group without comorbidities. Biological mechanism of immunosenescence provides general explanation of this finding. More morbid individuals have more weakened immune system which in turn lowers their immune response to the vaccine as evidenced by lower levels of antibodies (Schenkelberg, 2021). Due to the limited sample size, we combined all the comorbidities related to higher risks of COVID-19 (Centers for Disease Control and Prevention, 2022) into one group. The unbalanced representation of specific comorbidities in high and mid-dose groups does not allow to draw a firm conclusion about comorbidities role in the MVC-COV1901 induced immunogenicity. So far, cytosine phosphor- guanine (CpG-1018) used as the vaccine adjuvant has been shown to enhance immune responses in older adults with chronic kidney disease and diabetes (Janssen et al., 2015; Hyer and Janssen, 2019), but less is known about the other comorbidities. Targeting specific comorbidities in future trials may enhance scientific knowledge and clinical application of vaccination in more fragile populations.

Based on this analysis of safety and immunogenicity, we hypothesize that successful vaccination of older adults with high dose may enhance vaccine efficacy. Vaccine efficacy may be particularly enhanced if vaccination is protective in older individuals with comorbidities who have higher risks of COVID-19 infection, severe symptoms and hospitalization (Centers for Disease Control and Prevention, 2022). Although, the empirical determination of the antibody decay time is still ongoing, we assume that high dose will maintain the immune response for longer time. Nevertheless, individual with comorbidities and potential for adverse reactions, should carefully consider a choice of the high dose vaccines with a physician.

The stratified results by comorbidity status constitute the main strength of this study and the multi-center study design enhances the generalizability of our results. Data linking vaccine efficacy with comorbidities are often not collected because older adults with co-morbidities are usually excluded from vaccine clinical trials. In addition, older adults who are participants in phase 2 and 3 trials, generally are included because of an average-average health status (Soiza et al., 2021). Some limitations apply to our study. The results are restricted to Asian populations. This study included only older adults (> 65 years old), thus not allowing for direct comparisons with younger populations. Exclusion of participants with prior SARS-CoV-2 infection was dictated by the extremely low SARS-CoV-2 infection rates in Taiwan at the time of the study (Taiwan Centers for Disease Control, 2022). The ongoing and future trials after the COVID-19 outbreak will be able to compare populations with and without prior SARS-CoV-2 infection. Due to limited sample size, we combined diverse comorbidities into one group to maintain the statistical power of the analysis. Future trials should include more older adults with multiple chronic conditions to determine how different levels and types of morbidity influence immune response to vaccination. Moreover, observation for longer times and adjustments for other potential confounders, such as time of vaccination, are recommended. Assessment of cellular immunity in the future studies could provide a better understanding of the immune mechanisms involved.

Compromised immune systems in older adults and especially in those with comorbidities make them more vulnerable to COVID-19 infection, which increases the burden on families and healthcare systems. We demonstrated safety and immunogenicity of MVC-COV1901 at high and mid dose regimen in older adults and suggest the high dose as preferred option unless comorbidities suggest otherwise.

**Funding source**

Medigen Vaccine Biologics Corporation funded the trial and had a role in trial design.
Ethics approval

The clinical trial was approved by four Institutional Review Boards of the participating hospitals – National Taiwan University Hospital, Taipei Medical University Shuang-Ho Hospital, Linkou Chang Gung Memorial Hospital, and Hualien Tzu Chi Hospital. All participants provided written informed consent.

Declaration of Competing Interest

Chen C and Lien CE are employees of Medigen Vaccine Biologics Corporation. Waits A received consultancy fee from Medigen Vaccine Biologics Corporation. Other authors report no conflict of interest.

Acknowledgments

We would like to express our deep gratitude to all the study teams and the participants at the National Taiwan University Hospital, Taipei Medical University Shuang-Ho Hospital, Linkou Chang Gung Memorial Hospital, and Hualien Tzu Chi Hospital. We would like to thank the independent data monitoring committee – Feng-Yee Chang, Division of Infectious Disease and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, and members – Ching-Chuan Liu, Department of Pediatrics, College of Medicine, National Cheng Kung University; Chief, Division of Pediatric Infectious Diseases, National Cheng Kung University Hospital, Hsiao-Hui Sophie Tsou, Institute of Population Health Sciences, National Health Research Institutes, Po-Yen Chen, Section of Pediatric Infectious Disease, Department of Pediatrics, Taichung Veterans General Hospital, Ming-Fang Cheng, Pediatric Infectious Diseases & Pediatric Critical Care Medicine, Kaohsiung Veterans General Hospital.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ijid.2022.08.021.

References

Anderson EJ, Roupheal NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of Sars-CoV-2 Mrna-1273 Vaccine in Older Adults. N Engl J Med 2020;383:2427–38.

Centers for Disease Control and Prevention. Science Brief: Evidence Used to Update the List of Underlying Medical Conditions Associated with Higher Risk for Severe Covid-19, https://www.cdc.gov/coronavirus/2019-ncov/science/science-brief/underlying-evidence-table.html, Last Access: Apr 15, 2022.

Formica N, Mallory R, Albert G, Robinson M, Pleston JS, Cho I, et al. Different Dose Regimens of a Sars-CoV-2 Recombinant Spike Protein Vaccine (Nvax-Cov2373) in Younger and Older Adults: A Phase 2 Randomized Placebo-Controlled Trial. PLoS Med 2021;18.

Haas EJ, McLaughlin JM, Khan F, Angulo FJ, Anis E, Lipsitch M, et al. Infections, Hospitalisations, and Deaths Averted Via a Nationwide Vaccination Campaign Using the Pfizer–BioNTech Bnt162b2 Mrna Covid-19 Vaccine in Israel: A Retrospective Surveillance Study. Lancet Infect Dis 2021.

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of Nvax-Cov2373 Covid-19 Vaccine. N Engl J Med 2021;385:1172–83.

Hsieh S-M, Liu M-C, Chen Y-H, Lee W-S, Huang S-J, Cheng S-H, et al. Safety and Immunogenicity of Cog 1018 and Aluminum Hydroxide-Adjuvanted Sars–Cov–2 S-2 Protein Vaccine Mvck-Cov1901: Interim Results of a Large-Scale, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial. Taiwan: Lancet Respir Med, 2021.

Hyer RN, Janssen RS. Immunogenicity and Safety of a 2-Dose Hepatitis B Vaccine, Hbsag/Cpg 1018, in Persons with Diabetes Mellitus Aged 60–70 Years. Vaccine 2019;37:5854–61.

Jansen JM, Heyward WL, Martin JT, Janssen RS. Immunogenicity and Safety of an Investigational Hepatitis B Vaccine with a Toll-Like Receptor 9 Agonist Adjuvant (Hbsag-1018) Compared with a Licensed Hepatitis B Vaccine in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus. Vaccine 2015;33:833–7.

Jantzen R, Maltais M, Broet P. Socio-Demographic Factors Associated with Covid-19 Vaccine Hesitancy among Middle-Aged Adults During the Quebec’s Vaccination Campaign. Front Public Health 2022;10.

Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing Antibody Levels Are Highly Protective of Immunocompetence from Symptomatic Sars-Cov-2 Infection. Nat Med 2021;27:1205–11.

Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, et al. Safety and Immunogenicity of the Sars-Cov-2 Bnt162b1 Mrna Vaccine in Younger and Older Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Study. Nat Med 2021;27:1062–70.

Lien CE, Lin Y-J, Lin Y-L, Tai I-C, Chen C. The Age-Dependent Immunogenicity after Two Doses of Mvck-Cov1901 Vaccine. medRxiv: 2021.2021.2012.21267573.

Masuda T, Murakami K, Sugura K, Sakai S, Schuring RP, Mori M. Safety and Immunogenicity of Nvax-Cov2373 (Tak-019) Vaccine in Healthy Japanese Adults: Interim Report of a Phase I/II Randomized Controlled Trial. Vaccine 2022.

McElhaney JE, Verschoor CP, Andrew MK, Haynes L, Kuchel GA, Pawelec G. The Immune Response to Influenza in Older Humans: Beyond Immune Senescence. Immun Ageing 2020;17:1–10.

Naaber P, Tierel L, Kangro K, Sepp E, Jurijsen V, Adamson A, et al. Dynamics of Antibody Response to Bnt162b2 Vaccine after Six Months: A Longitudinal Prospective Study. Lancet Reg Health Eur: 2021.

Our World in Data. Share of People Who Completed the Initial Covid-19 Vaccination Protocol by Age. https://ourworldindata.org/grapher/covid-completed-vaccinated-by-age, Last Access: Apr 14, 2022.

Ramasamy MN, Minassian AM, Ewer KJ, Fixman AL, Folegatti PM, Owens DR, et al. Safety and Immunogenicity of Chadox1 Ncov-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (Cov002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial. Lancet 2020;396:1979–93.

Schenkelberg T. Vaccine-Induced Protection in Aging Adults and Pandemic Response. Biochem Biophys Res Comm 2021;538:218.

Siu YF, Cao Y, Shum DHK, Perceptions of and Hesitancy toward Covid-19 Vaccination in Older Chinese Adults in Hong Kong: A Qualitative Study. BMC Geriatr 2022;22:288.

Soiza RL, Scicluna C, Thompson EC. Efficacy and Safety of Covid-19 Vaccines in Older People. Age Ageing 2021;50:279–83.

Taiwan Centers for Disease Control. Weekly Number of Suspected Covid-19 Cases Reported, https://www.cdc.gov.tw/En, Last Access: Aug 22, 2022.

Tan M, Straughan PT, Cheong G. Information Trust and Covid-19 Vaccine Hesitancy Amongst Middle-Aged and Older Adults in Singapore: A Latent Class Analysis Approach. Soc Sci Med 2022;296.

US Food and Drug Administration. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical, Last Access: Aug 22, 2022.

Veronesi N, Petrovic M, Benetos A, Denkinger M, Gudmundsson A, Knol W, et al. Underrepresentation of Older Adults in Clinical Trials on Covid-19 Vaccines: A Systematic Review. Ageing Res Rev 2021;71.

World Health Organization. Who Coronavirus (Covid-19) Dashboard, https://covid19.who.int/, Last Access: Aug 22, 2022.